| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/23/2005 | US20050137179 Potent antagonists of chemokine receptors and controls in drug screening assays; antiallergens, antiinflammatory, antifibrotic, antiarthritic, and anticarcinogenic agents; inflammatory bowel disease |
| 06/23/2005 | US20050137178 Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators |
| 06/23/2005 | US20050137177 Ester combination local anesthetic |
| 06/23/2005 | US20050137176 Receptor ligands for cosmetics or skins for maintaining cutaneous homeostasis |
| 06/23/2005 | US20050137175 Composition with ecdysteroid with water or milk for lotions for skin and applying to prevent hair loss |
| 06/23/2005 | US20050137172 Haloacetamide and azide substituted compounds and methods of use thereof |
| 06/23/2005 | US20050137170 Novel phosphorous containing steroid mimics |
| 06/23/2005 | US20050137169 Vinca derivatives |
| 06/23/2005 | US20050137167 Inhibiting FGF growth factor with heparins; antitumor agents; angiogenesis inhibitor; antidiabetic agent treating diabetic retinopathy; antiinflammatory agent; treating retrolenticular fibroplasia, psoriasis, restenosis after angioplasty and after coronary by-pass; chemical intermediates; drug delivery |
| 06/23/2005 | US20050137166 Use of cooling agents to relieve mild ocular irritation and enhance comfort |
| 06/23/2005 | US20050137165 Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
| 06/23/2005 | US20050137164 comprising topical mixtures of non-steroidal anti-inflammatory drug (NSAID) and carriers |
| 06/23/2005 | US20050137163 hydrophobic heteropolysaccharide complexes with tetra alkyl ammonium halides, for incorporation with biological scaffolds used maintenance and regeneration of muscles |
| 06/23/2005 | US20050137161 Methods and compositions for treating hepatitis C virus |
| 06/23/2005 | US20050137159 Methods compositions and articles of manufacture for modulating bone growth |
| 06/23/2005 | US20050137158 Methods for targeting RNA molecules |
| 06/23/2005 | US20050137157 administering polynucleotides coupled to thymidine kinase genes, that convert prodrugs such as acyclovir, ganciclovir, fialuridine or 6-methoxypurine arabinoside, to cytotoxic compounds, used for tissue targeted therapy in the treatment of pancreatic cancers |
| 06/23/2005 | US20050137150 Forms of 5-azacytidine |
| 06/23/2005 | US20050137149 Activating using imidazoleacetic acid compound; receptor moderator signal transduction; relasing arachidonic acid; hypotensive agents; central nervous system disorders; psychological disorders |
| 06/23/2005 | US20050137148 treating an infectious disease associated with narrowing or obstruction of a body passageway by delivering to an external portion of the body passageway an antibiotic; infections such as pelvic inflammatory disease, urethritis, or tuberculosis |
| 06/23/2005 | US20050137147 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| 06/23/2005 | US20050137146 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 06/23/2005 | US20050137144 synergistic admnistration of a weight-loss promoting anticonvulsant of of zonisamide or topiramate, and a norepinephrine or dopamine agonist; hypotensive, antidiabetic, anticholesterol agents |
| 06/23/2005 | US20050137143 Such as 3-( beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)-methyl]-1-isopropyl-5-methylpyrazole; for prevention/treatment of diabetes, diabetic complications, and/or obesity; sodium glucose transport protein inhibitors |
| 06/23/2005 | US20050137142 treating nervous system diorders by administering inhibitors of glutaminyl cyclase and optionally inhibitors of propyl endopeptidases, dipeptidyl aminopeptidases, secretases, endopeptidase, angiotensin converting enzyme and neuropeptide Y receptor ligands, agonists or antagonists; enzyme inhibitors |
| 06/23/2005 | US20050137141 antiviral agents conjugated to amino acids, to enhance bioavailability |
| 06/23/2005 | US20050137139 Peptidomimetic compounds, useful as antiviral agents; used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection |
| 06/23/2005 | US20050137125 concurrent administration of cysteamine hydrochloride with metformin |
| 06/23/2005 | US20050137124 Agents for intravitreal administration to treat or prevent disorders of the eye |
| 06/23/2005 | US20050137123 administering drugs that interacts with genes that code for serum amyloid A (SAA) receptors, the interaction decreases the expression of SAA; gene expression inhibitors; treatment of vision defects |
| 06/23/2005 | US20050137122 Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance |
| 06/23/2005 | US20050137121 Inhibition of invasive remodelling |
| 06/23/2005 | US20050136537 Modulating sirtuin deacetylase protein; apoptosis; using flavone, stilbene, isoflavone, sphingosine; stroke; cardiovascular disorders; antiarthritic agents; Alzheimer's disease |
| 06/23/2005 | US20050136502 Treatment of disorders associated with elevated blood glucose or blood pressure |
| 06/23/2005 | US20050136474 Truncation SELEX method |
| 06/23/2005 | US20050136444 Drug screening |
| 06/23/2005 | US20050136400 NS3-NS4A protease resistance mutants |
| 06/23/2005 | US20050136398 Contacting a candidate compound having an esterified phosphonate or carboxyl group with GS-9005 ester hydrolase B and identifying the compound as a suitable prodrug by the presence of a phosphonic acid or carboxylic acid group; particularly identifying compounds having therapeutic activity against HIV |
| 06/23/2005 | US20050136397 Methods and compositions for identifying therapeutic compounds |
| 06/23/2005 | US20050136396 Contacting a candidate compound having an esterified phosphonate or carboxyl group with GS-9005 ester hydrolase A and identifying the compound as a suitable prodrug by the presence of a phosphonic acid or carboxylic acid group; particularly identifying compounds having therapeutic activity against HIV |
| 06/23/2005 | US20050136141 Compositions of and derived from strawberry and raspberry and therapeutic uses thereof |
| 06/23/2005 | US20050136140 Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| 06/23/2005 | US20050136139 Sensitive skin care and protection; long lasting, sustained effect; bioavailability |
| 06/23/2005 | US20050136136 Method for isolating terpene trilactones (ginkgolides, bilobadide) from leaves and pharmaceutical powders of ginkgo biloba |
| 06/23/2005 | US20050136135 Chitosan-psyllium complexes and methods for making and using same |
| 06/23/2005 | US20050136134 Composition for the control of pathogenic microorganisms and spores |
| 06/23/2005 | US20050136133 Administering an anti-allergy composition of a wood-vinegar distilled solution, colorless and transparent |
| 06/23/2005 | US20050136131 Adding glycine to a first saturated brine, evaporating the first saturated brine and glycine to obtain:crystals comprising a high content of glycine, and mother liquor;washing the crystals with a second saturated brine to obtain:rhombic dodecahedron shaped salt comprising 0.5 to 1.0% glycine |
| 06/23/2005 | US20050136130 Dietary supplements for inhibiting the progression of macular degeneration and promoting healthy vision |
| 06/23/2005 | US20050136129 Administering to postsurgery and/or immobile persons; comprised of proteins, carbohydrates, fats with equivalents of arginine, ascorbic acid and alpha tocopherol |
| 06/23/2005 | US20050136128 Dry powders of metal-containing compounds |
| 06/23/2005 | US20050136127 Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors |
| 06/23/2005 | US20050136122 Preparing and using crosslinked, water insoluble, hydrated hyaluronic acid gel particles; in vivo biostability and mechanical properties, usability; ease of injection through fine needles |
| 06/23/2005 | US20050136117 Amoxicillin and clavulanate dry powder for reconstitution with water into a multiple dose suspension; carboxymethylcellulose sodium pH stabilizer |
| 06/23/2005 | US20050136116 Thickener of hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydropropyl methyl cellulose, hydroxy ethyl methylcellulose, hydroxypropyl methylcellulose; and buffer of potassium or sodium phosphate; shelf life; no refrigeration |
| 06/23/2005 | US20050136113 Dosage form comprising a semipermeable wall defining a cavity having an exit orifice; expandable layer; flow control agent; sustained release push delivery devices having high drug loading with minimized residue |
| 06/23/2005 | US20050136111 Novel composition and use |
| 06/23/2005 | US20050136110 In a matrix-forming, hydrophilic or hydrophobic polymer comprising a cellulose ether or ester of hydroxypropyl methyl cellulose, hydroxyethycellulose, hydroxypropycellulos, methycellulose, ethycellulose and/or carboxymethyl cellulose |
| 06/23/2005 | US20050136109 Oral extended release drug or veterinary composition in compressed tablet form comprising venlafaxine, or an enantiomeric form or water soluble salt thereof and a carboxyvinyl polymer such as Carbopol"; antidepressants, bioavailability |
| 06/23/2005 | US20050136108 Stepwise delivery of topiramate over prolonged period of time |
| 06/23/2005 | US20050136107 Hydrophilic ydroxypropyl (methyl) cellulose, , hydroxyethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyvinylpyrrolidone, crotonic acid-vinyl acetate copolymer, maleic anhydride-methyl vinyl ether copolymer, polyoxyethylene glycol; low viscosity |
| 06/23/2005 | US20050136103 Compositions capable of facilitating penetration across a biological barrier |
| 06/23/2005 | US20050136102 Enhanced transport using membrane disruptive agents |
| 06/23/2005 | US20050136085 Panthenol and natural organic extracts for reducing skin irritation |
| 06/23/2005 | US20050136069 Immunogenic portion of Mycobacterium tuberculosis proteins and monophosphoryl lipid A as adjuvant; vaccines |
| 06/23/2005 | US20050136065 Use of small molecule compounds for immunopotentiation |
| 06/23/2005 | US20050136047 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 06/23/2005 | US20050136041 Transgenic cell comprising nucleotide sequences coding erythropoietin and/or glucagon-like peptides for use in treatment and prevention of blood and metabolic disorders; somatic and germ cell gene therapy; tissue engineering |
| 06/23/2005 | US20050136038 Organic binder having an affinity for the calcium phosphate particles, stem cells, osteogenic cells, and/or osteoprogenitor cells, and a buffer; can be injected to repair an osseous defect |
| 06/23/2005 | US20050136031 Chemically modified small molecules |
| 06/23/2005 | US20050136030 with cholestyramine or colestipol; kit for treating obesity |
| 06/23/2005 | US20050136024 Treating skin disorders with complexes prepared by a metathesis reaction between bioactive monomeric or polymeric cationic molecule and a bioactive monomeric or polymeric anionic molecule |
| 06/23/2005 | US20050136015 Applying 5-chlorosalicylic acid, 5-bromosalicylic acid for treating skin, and nail disorders, dandruff, acne, excess sebum production, enlarged skin pore size, and blackheads; cosmetics |
| 06/23/2005 | US20050136010 Treatment of chronic obstructive pulmonary disease, by administering inhalant with particulate carrier or diluent selecting from saccharide, a sugar alcohol or lactose, in an amount of from 400 mu g to 5000 mu g per mu g of active ingredient |
| 06/23/2005 | US20050136009 metered dosage inhaler having a metering valve to drug deliver a dose of aerosol suspension formulations comprising mometasone furoate, Formoterol, Formoterol Fumarate and HFA 227; drug delivery device |
| 06/23/2005 | US20050132948 Method for the production of low defect density silicon |
| 06/23/2005 | DE60108272T2 Pharmazeutische zusammensetzung enthaltend (-)-secoisolariciresinol A pharmaceutical composition comprising (-) - Secoisolariciresinol |
| 06/23/2005 | DE10356410A1 Phosphororganische Verbindungen und deren Verwendung Organophosphorus compounds and their use |
| 06/23/2005 | DE10356362A1 Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of anxiety disorders |
| 06/23/2005 | DE10356346A1 Erfindung betreffend Prophylaxe und Therapie von Erkrankungen, die durch Thrombusbildung verusacht oder mit versacht werden Concerning invention prophylaxis and therapy of diseases verusacht by thrombus or plunged |
| 06/23/2005 | DE10356248A1 Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden A pharmaceutical composition for the treatment of rhinitis |
| 06/23/2005 | DE10356112A1 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff A pharmaceutical composition comprising a beta 3-adrenoceptor agonist and an eingreifendem in the Prostglandinstoffwechsel agent |
| 06/23/2005 | DE10355716A1 Kosmetische Zubereitungen mit einem Gehalt Kreatin und/oder Kreatinderivaten und/oder Kreatinin und/oderKreatininderivaten und organischen Verdickern Cosmetic preparations containing creatine and / or creatine derivatives and / or creatinine and / oderKreatininderivaten and organic thickeners |
| 06/23/2005 | DE10355461A1 Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases |
| 06/23/2005 | DE10355304A1 Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel New 8- (piperazin-1-yl) -and 8 - ([1,4] diazepan-1-yl) -xanthines, their preparation and their use as medicaments |
| 06/23/2005 | DE10353832A1 Solid pharmaceutical composition containing tropane type inhibitor of neurotransmitter reuptake, useful for treating central nervous system disorders |
| 06/23/2005 | DE10353673A1 Verfahren zur Reinigung von Climbazol A process for purifying climbazole |
| 06/23/2005 | DE10353657A1 New quinolonyl- or benzopyranonyl-substituted indole derivatives are 5HT(1A)- and/or 5HT(1D)-agonists useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents |
| 06/23/2005 | CA2832293A1 Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| 06/23/2005 | CA2552279A1 Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| 06/23/2005 | CA2550136A1 Microcrystal and medicinal preparation containing the same |
| 06/23/2005 | CA2550130A1 Agents for preventing and/or treating higher brain dysfunctions |
| 06/23/2005 | CA2550105A1 Indole derivatives for the treatment of bone diseases |
| 06/23/2005 | CA2549736A1 Cationic substituted benzofurans as antimicrobial agents |
| 06/23/2005 | CA2549574A1 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| 06/23/2005 | CA2549413A1 Glycopegylated factor ix |
| 06/23/2005 | CA2549408A1 Adhesion inhibition of micro organisms by non-ionic surfactants |
| 06/23/2005 | CA2549401A1 Heterocyclic anti-migraine agents |
| 06/23/2005 | CA2549384A1 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 06/23/2005 | CA2549355A1 The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same |